Li Yi-Lin, Yao Cheng-Jiao, Lei Rong, Xie Fengjiao, Xiong Qin, Luo Li-Hong, Feng Pei-Min
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
North Sichuan Medical College.
Medicine (Baltimore). 2020 Nov 25;99(48):e23457. doi: 10.1097/MD.0000000000023457.
As a traditional Chinese medicine external treatment method, acupuncture is characterized by simple operation, significant treatment effect and few side effects. Tong-Xie-Yao-Fang (TXYF), a Chinese patent medicine, combined with acupuncture has been widely used on treating Diarrhea Predominant Irritable Bowel Syndrome (IBS-D). However, the efficacy and safety of TXYF combined with acupuncture for the treatment of IBS-D are unclear. This study aims to investigate verify the efficacy and safety of TXYF combined with acupuncture for IBS-D.
Randomized controlled trials of TXYF combined with acupuncture for all IBS-D will be searched in PubMed, the Cochrane Library, Embase, Web of Science, the China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biomedical Literature Database from inception to October 20, 2020. And Baidu Scholar, Google Scholar, International Clinical Trials Registry Platform, and Chinese Clinical Trials Registry will be searched to obtain more relevant studies comprehensively. The methodological qualities, including the risk of bias, will be evaluated using the Cochrane risk of bias assessment tool, while confidence in the cumulative evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Two researchers will perform data extraction and risk of bias assessment independently. Statistical analysis will be conducted in RevMan 5.3.
Based on the current evidence, the potential rank of the efficacy and safety of TXYF plus acupuncture for IBS-D will be assessed.
The findings of the study will provide helpful evidence for the efficacy and safety of TXYF combined with acupuncture in the treatment of IBS-D, facilitating clinical practice and further scientific studies.
针灸作为一种中医外治疗法，具有操作简便、治疗效果显著、副作用少的特点。痛泻要方（TXYF），一种中成药，联合针灸已广泛应用于腹泻型肠易激综合征（IBS-D）的治疗。然而，TXYF联合针灸治疗IBS-D的疗效和安全性尚不清楚。本研究旨在探讨验证TXYF联合针灸治疗IBS-D的疗效和安全性。
从创刊至2020年10月20日，在PubMed、Cochrane图书馆、Embase、Web of Science、中国知网、万方数据库、中国科技期刊数据库和中国生物医学文献数据库中检索TXYF联合针灸治疗所有IBS-D的随机对照试验。同时检索百度学术、谷歌学术、国际临床试验注册平台和中国临床试验注册中心，以全面获取更多相关研究。将使用Cochrane偏倚风险评估工具评估包括偏倚风险在内的方法学质量，同时使用推荐分级评估、制定和评价（GRADE）方法评估对累积证据的信心。两名研究人员将独立进行数据提取和偏倚风险评估。将在RevMan 5.3中进行统计分析。
基于现有证据，将评估TXYF加针灸治疗IBS-D的疗效和安全性的潜在排名。
本研究结果将为TXYF联合针灸治疗IBS-D的疗效和安全性提供有益证据，促进临床实践和进一步的科学研究。
